Search Results

U.S. FRIB Secures Contract from Naval Nuclear Laboratory to Develop Quantum-Classical Hybrid Nuclear Reaction Calculation Methods

A research project at the Facility for Rare Isotope Beams (FRIB) at Michigan State University, led by Dean Lee, Professor of Physics at FRIB, Professor in the Department of Physics and Astronomy at Michigan State University, and Head of the Theoretical Nuclear Science Department at FRIB, has received one-year contract support from the Naval Nuclear Laboratory. The laboratory is managed by Fluor Marine Propulsion. The project will study how to combine quantum computers with classical computers to improve the accuracy of predictions for neutron interactions with matter. This also represents the first phase of a five-year plan aimed at developing and evaluating new computational tools for nuclear science. In nuclear physics research, accurately predicting how neutrons interact with atomic nuclei...

2026-08-18

China's First Qualification for Radiation Health Testing and Evaluation of BNCT Equipment Approved

Recently, the Beijing Municipal Health Commission, in accordance with the "Administrative Measures for Radiation Health Technical Service Institutions" (Guoweiban ZhiJian Fa [2026] No. 1), organized experts to conduct on-site reviews of two qualification expansion applications submitted by the National Center for Occupational Safety and Health under the National Health Commission. The projects include performance testing and evaluation of Boron Neutron Capture Therapy (BNCT) equipment and thyroid iodine-131 testing. During the review process, the expert panel conducted a comprehensive examination of the center's management system, personnel allocation, instruments and equipment, and technical capabilities related to radiation health testing and evaluation through document review, technical inquiries, on-site practical operations, and simulated demonstrations...

2026-08-12

China Bio-Pharma: Enters Cooperation Agreement with Stella Pharma on Boron Neutron Therapy Drug

China Bio-Pharma Holdings Limited announced on August 12 that the company, Pengbo (Hainan) Boron Neutron Medical Technology Co., Ltd., and Japan's Stella Pharma Corporation signed a legally binding Master Cooperation Agreement on August 11, 2026, to jointly advance the development and commercialization of Steboronine in China. Steboronine is described in the announcement as the world's first approved boron neutron therapy drug, applied in Boron Neutron Capture Therapy (BNCT). Under the agreement, the cooperation between the two parties is divided into a development phase and a commercialization phase. During the development phase, the cooperation aims to leverage real-world data, real-world evidence, and real-world studies generated by the China Bio-Pharma Group to facilitate Stella Pharma in obtaining and maintaining, as soon as possible, marketing approval from China's National Medical Products Administration (NMPA) for Steboronine for the treatment of head and neck cancer; after Stella Pharma obtains marketing and manufacturing approval from the Japanese government for Steboronine for meningioma, the relevant China filings may also be extended to the meningioma indication.

2026-08-12

Fujita Health University in Japan Advances Research on Expanding BNCT Indications for Deep-Seated Cancers, to Conduct 18F-FBPA PET Exploratory Evaluation

On August 10, Stella Pharma Corporation of Japan announced that it is collaborating with Fujita Health University and other institutions to advance research and development aimed at expanding Boron Neutron Capture Therapy (BNCT) to deep-seated cancers. As part of this project, Stella Pharma will participate in an exploratory study on 18F-FBPA uptake capacity in deep-seated cancers conducted by Fujita Health University. The study will use 18F-FBPA PET to evaluate the tumor accumulation of boron drugs used in BNCT in deep-seated cancers, and based on the findings, explore the possibility of expanding BNCT indications in the future. The study plans to collect data from 50 cases, including pancreatic cancer, hepatocellular carcinoma, and biliary tract cancer, to accumulate foundational evidence needed for the development of BNCT for deep-seated cancers. BNC...

2026-08-11

International Team Measures Niobium-94 Neutron Reactions, Explaining Anomalous Molybdenum-94 Abundance in the Solar System

An international team of physicists has, for the first time, conducted a comprehensive study of the interactions between neutrons and the niobium-94 isotope. The findings have been published in Physical Review Letters. The study suggests that the elevated abundance of molybdenum-94 in the primordial material of the solar system can be explained by a series of neutron-involving nuclear reaction processes inside old stars, without requiring the introduction of previously unknown special formation mechanisms. The research was led by Alberto Mengoni, a researcher at the Italian National Institute for Nuclear Physics. The team conducted experiments using the n_TOF facility at CERN, focusing on tracking the interactions between neutrons and niobium-94 atoms. The n_TOF facility is used to...

2026-08-11

Russia's Vector Research Center Proposes Quantum Dots for Boron Delivery in Neutron Capture Therapy

Russia's Vector Research Center has proposed using quantum dots as targeted boron delivery systems in boron neutron capture therapy (BNCT) to explore more precise approaches to tumor treatment. Yuri Tumanov, the center's chief researcher, presented this research progress at a conference on engineering biology and biopharmaceuticals. Boron neutron capture therapy is a cancer treatment method that combines boron-containing drugs with neutron irradiation. The basic concept involves first allowing boron-containing drugs to accumulate in tumor cells, then subjecting the patient to neutron irradiation, which triggers a nuclear reaction that releases energy concentrated within boron-containing cancer cells, thereby destroying tumor cells. How to construct boron delivery systems that are low-toxicity, highly efficient, and capable of participating in targeted tumor destruction remains one of the key challenges in this field...

2026-08-01